CorMedix Inc. (CRMD) is highlighted as one of the most undervalued biotech stocks to buy now. Needham analyst Serge Belanger maintains a Buy rating on CRMD with a price target of $20.00, citing strategic growth potential. The company’s recent acquisition of Melinta Therapeutics is expected to boost sales significantly.

The acquisition positions CRMD to expand its portfolio in the hospital sector through further product acquisitions and business development. CorMedix Inc. is a medical device and biopharmaceutical company focused on developing therapeutics to treat and prevent diseases. While CRMD shows investment potential, other AI stocks may offer greater upside potential and lower risk.

For those seeking an extremely undervalued AI stock with potential benefits from Trump-era tariffs and the onshoring trend, check out the free report on the best short-term AI stock. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Needham Maintains a Buy Rating on CorMedix (CRMD) With a $20 PT